Home » Newsletters » BioWorld

BioWorld

April 18, 2011

View Archived Issues

Academia-Fueled R&D Helps Gilead's Move into Oncology

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

FDA Approvals in March

Phase I Clinical Trials Update: March 2011

Phase II Clinical Trials Update: March 2011

Phase III Clinical Trials Update: March 2011

Non-U.S. Clinical Trials & Regulatory Actions: March 2011

FDA Submissions, Approvals & Other Actions: March 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Big Rewards, Bigger Risks? The Truth About Antibodies

It's no secret that monoclonal antibodies (mAbs) have been hot biotech property for a while. Read More

IPO Pricing, Shares Offered: It's a Numbers Game

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...